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Available online 9 November 2016Age of onset inmultiple sclerosis (MS) exerts an inﬂuence on the course of disease. This study examinedwhether
global and regional brain volumes differed between “younger” and “older” onset MS subjects whowerematched
for short disease duration, mean 1.9 years and burden as measured by the MS Severity Score and relapses.
21 younger-onsetMS subjects (age 30.4± 3.2 years) were comparedwith 17 older-onset (age 48.7± 3.3 years)
as well as age-matched controls (n=31, 31.9± 3.5 years and n=21, 47.3 ± 4.0 years). All subjects underwent
3D volumetric T1 and T2-FLAIR imaging. White matter (WM) and greymatter (GM) lesions were outlinedman-
ually. Lesions were ﬁlled prior to tissue and structural segmentation to reduce classiﬁcation errors.
Volume loss versus control was predominantly in the subcortical GM, at N13% loss. Younger and older-onset MS
subjects had similar, strong excess loss in the putamen, thalamus, and nucleus accumbens. No excess losswas de-
tected in the amygdala or pallidum. The hippocampus and caudate showed signiﬁcant excess loss in the younger
group (p b 0.001) and a strong trend in the older-onset group.
These results provide a potential imaging correlate of published neuropsychological studies that reported the asso-
ciation of younger age at disease onsetwith impaired cognitive performance, including decreasedworkingmemory.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Multiple sclerosis
Magnetic resonance imaging
Image analysis
Grey matter
Atrophy1. Introduction
Multiple Sclerosis (MS) is a chronic inﬂammatory disease of the cen-
tral nervous system, most commonly presenting in young adults as re-
lapsing remitting (RRMS) or later in life as progressive disease (either
primary- or secondary-progressive: PPMS or SPMS, respectively), and
associated, especially in the latter, with signiﬁcant neurodegenerative
pathological features. The notion ofMS as a disease exclusively affecting
the white matter (WM), with multifocal demyelination, is diminishing
(Friese et al., 2014; Vigeveno et al., 2012). Indeed, WM lesion load de-
tected by MRI is only weakly correlated with clinical symptoms
(Zivadinov and Cox, 2007). There is a growing body of evidence from
both pathology andMRI to suggest that greymatter (GM) degeneration
is prevalent in MS (Bermel et al., 2003), (Bakshi et al., 2005), (Chard et
al., 2004), (Sanﬁlipo et al., 2006) and may be a stronger predictor ofan).
. This is an open access article underclinical decline than WM measures (Fisniku et al., 2008; Pirko et al.,
2007). Information pertaining to the relative atrophy rate of cortical
and subcortical GM regions in early MS, and their role in the disease
course, remains a topic of study (Bergsland et al., 2012).
Studies of GMatrophy inMS can be confounded by segmentation er-
rors arising from theMS lesions, which result inmisclassiﬁcation ofWM
regions as GM, and vice versa. One way to circumvent this issue is to
mask the lesion areas after global tissue segmentation, but the segmen-
tation error could potentially extend beyond the locality of the lesion it-
self. Thus, lesionﬁlling prior to segmentation of the anatomicalMRI data
has been proposed (Chard et al., 2010), and has shown superior seg-
mentation results over retrospective lesion masking (Battaglini et al.,
2012). However, lesion ﬁlling is not yet universally adopted in image
analysis procedures.
The age of onset of MS is relatively varied and it is yet unclear what
role GM changes play in this. An older age of RRMS onset is associated
with an increased risk of conversion to the more disabling SPMS, inde-
pendent of disease duration and early relapse frequency (Scalfari et
al., 2011). Transformation from RRMS to SPMS may therefore be inthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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disease-speciﬁc pathology. In other work, myelin integrity (as mea-
sured by magnetization transfer MRI) has been shown to be indepen-
dently affected by age in early MS (Newbould et al., 2014), so GM may
be similarly affected.
The objectives of this study are therefore three-fold: (i) to establish
whether cortical or subcortical GM atrophy dominates in early MS; (ii)
to investigate whether the degree of GM atrophy differs between youn-
ger and older-onset MS patients of matched clinical status – reﬂecting
the effect of age on CNS damage and repair, independent of disease du-
ration; and (iii) to propose an image analysis workﬂow for reproducible
and standardized quantiﬁcation of the required imaging endpoints for
such analysis.
We recruited two age groups ofMS patientswith short disease dura-
tion fromwithin awell-characterised research cohort. The only factor of
signiﬁcant demographic difference between the two MS groups was
age. Comparison of these with ‘younger’ and ‘older’ groups of age-
matched healthy controls enabled cross-sectional analysis of GM (and
WM) atrophy in each age group.
2. Methods
2.1. Subjects
A total of 38MSpatients and 52 age-matched controlswere involved
in this study (Table 1). Subjects gave written informed consent, and the
studies had ethical approval from the National Research Ethics Service.
2.2. MRI acquisition
All subjects were imaged on a 3T Verio clinical MR system (Siemens
Healthcare, Erlangen, Germany; VB17), using a 12-channel phased-
array head coil. A T1-weighted 3D MPRAGE volume acquisition was
based on the ADNI-GO recommended parameters (Jack et al., 2008)
but with 1 mm3 isotropic resolution and parallel imaging (PI) factor of
2. A T2-weighted ﬂuid-attenuated inversion recovery (T2-FLAIR)
volume was acquired with 1 mm3 isotropic resolution using a 3D T2w
variable-refocusing angle turbo spin echo readout (Mugler and
Brookeman, 2003), with 160 sagittal sections captured in a single 3D
slab with the following parameters: echo time (TE) 395 ms, repetition
time (TR) 5 s, inversion time (TI) 1800 ms, 250 × 250 mm ﬁeld-of-
view, and a PI factor of 2.
2.3. Data analysis
Images were processed following the analysis workﬂow depicted in
Fig. 1. Each subject's T2-FLAIR volume was co-registered to their
MPRAGE using the rigid-body transformation of FLIRT (Jenkinson et
al., 2002). To improve the subsequent tissue segmentations (Popescu
et al., 2012), the MNI152 template was aligned using the afﬁneTable 1
Demographics: four groups. Table of demographics for the four subject groups (both controls an
(SD). NA = not applicable.
Younger
Control
Younger
MS
Older
Control
Older MS p (yC/yMS) p (
N 31 21 21 17
Age (years) 31.9 (3.5) 30.4 (3.2) 47.3 (4.0) 48.7 (3.3) 0.86 b0
Gender (M/F) 18/13 2/19 12/9 5/12 b0.001 1.0
D.D. (years) NA 2.3 (1.6) NA 2.4 (1.2) NA NA
EDSS NA 3.0 (1.2) NA 4.1 (1.3) NA NA
MSSS NA 5.5 (1.6) NA 6.3 (1.7) NA NA
Relapses (#) NA 2.0 (0.8) NA 1.8 (0.8) NA NA
All RRMS 15 RRMS 2 SPMSregistration of FLIRT (Jenkinson et al., 2002) to the same MPRAGE.
This transform was then applied to a rectangular mask covering the
MNI152 template, and the transformed mask applied to the MPRAGE
to remove excess neck that can corrupt brain extraction tools
(Popescu et al., 2012). After masking, the anatomical scans were seg-
mented using additional FSL tools: (i) SIENAX (Smith et al., 2002) for
scaled tissue volumes of WM, GM, and cortical GM, normalized for sub-
ject head size; and (ii) FIRST (Patenaude et al., 2011) for subcortical grey
matter volumes of the putamen, caudate, thalamus, hippocampus,
amygdala, accumbens, and pallidum. Subcortical GM structures were
multiplied by the SIENAX volume-correction factor to normalize the
volumes across subjects. For the MS patients, additional processing
steps were performed. WM and GM lesions were ﬁlled (Battaglini et
al., 2012) using themanually deﬁned lesionmasks before the tissue seg-
mentations. After segmentation, correct assignment of WM and GM le-
sions to WM and GM respectively was checked by masking the partial
volume estimates inside the lesion masks. Finally, the recommended
brain extraction tool (BET) parameters (of B and f = 0.1) for bias ﬁeld
estimationwith SIENAX inMS subjects (Popescu et al., 2012)were used.
Lesion segmentation was performed using a semi-automated inten-
sity-based thresholding technique with manual correction (Jim Version
6.0, Xinapse) by a trained observer and corroborated by a second expe-
rienced neuroradiologist, both blinded to subject age and clinical status.
GM lesions were segmented from T2-weighted FLAIR images and con-
ﬁrmed on the T1-weighted MPRAGE images. FLAIR images were used
for WM lesion deﬁnition, due to high lesion conspicuity and detectabil-
ity on these scans. Fig. 2, top row, shows the segmentation results of the
GM and WM lesions in one MS patient.
The scaled SIENAX output volumes (in units of mm3) of GM, WM,
and cortical GM (cGM) summed across each hemisphere are termed
the ‘global’ tissue volumes in this study and were used for comparison
of global tissue volumes across the different groups. We also computed
a tissue volume for the subcortical and nonperipheral GM (scGM), by
subtraction of the scaled cGM from the scaled GM volume, giving a
fourth global tissue volume for group comparison (Fig. 2: bottom
row). It should be noted that this scGM volume is not an accurate seg-
mentation of subcortical deep grey matter structure volumes, but pro-
vides a ﬁrst-pass indication of the subcortical tissue volume
differences between the groups before formal segmentation of individ-
ual subcortical greymatter structure volumes (Fig. 2: bottom right). For
example, the scGM includes the allocortex structures such as the hippo-
campus. The scaled FIRST output volumes for the deﬁned individual
deep grey matter regions (also in units of mm3) were compared across
groups, to investigate ‘local’ (subcortical) tissue volume changes.
Younger and older groups were combined to investigate tissue vol-
ume differences between controls andMS patients. Then, age-group re-
lated differenceswere explored. Differences for agewere assessed using
a univariate analysis of variance (ANOVA)with four groups. For the two
MS groups, differences for the Expanded Disability Status Scale (EDSS),
MS Severity Score (MSSS) (Roxburgh et al., 2005), and disease durationdMS patients, young and old) and results of group comparisons. Values reported asmean
yC/oC) p (yC/oMS) p (yMS/oC) p (yMS/oMS) p (oC/oMS)
.001 expected b0.001 expected b0.001 expected b0.001 expected 1.00
0 0.75 0.003 0.21 0.11
NA NA 0.89 NA
NA NA 0.008 NA
NA NA 0.13 NA
NA NA 0.50 NA
Fig. 1. Image analysisworkﬂow. The image analysisworkﬂow for extractingmeasures of scaled tissue volumes from the input T1-weightedMPRAGE scans ofMS patients (left) and healthy
controls (right). Blue boxes signify 3D image volumes, whilst green boxes signify processing steps. The ﬁnal numerical outputs are colored in purple.
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explored with a Chi-squared test. For volumetric analysis, ANCOVA
was used with either two or four groups as the ﬁxed, between-sub-
jects factor, and gender as a covariate throughout. In the two-group
analysis where younger and older groups were combined, age was
also used as a covariate. All statistical tests were performed in SPSS
v20.0 (IBM Corporation, Armonk NY). All p-values are reported with-
out correction for multiple comparisons. Comparisons that survive
Bonferroni correction for the multiple comparisons amongst groups
or regions with a threshold of p b 0.05 are marked in the ﬁgures and
tables.
3. Results
3.1. Subjects
The demographics of the younger and older MS patients and con-
trols are summarised in Table 1. The mean age at the time of the MRI
scan was 31.9 ± 3.5 years (mean± SD) in the younger control group
(n = 31, 18M/13F), 30.4 ± 3.2 years in the younger MS group (n =
21, 2M/19F), 47.3 ± 4.0 years in the older control group (n = 21,
12M/9F) and 48.7 ± 3.3 years in the older MS group (n = 17, 5M/
12F). According to the revised McDonald's criteria, a diagnosis of
RRMS was made for all of the younger MS patients and 15 (out of
17) of the olderMS patients. Gender differences were found betweenthe two younger groups and also between the younger MS and the
older controls. EDSS was greater in the older group, though the
MSSS did not differ between MS groups. The number of recent re-
lapses (2.0 ± 0.8 versus 1.8 ± 0.8) also did not differ between the
MS groups.
3.2. Global GM and subcortical GM atrophy matched in each age group
Fig. 3a shows the scaled global tissue volumes (WM, GM, cGM,
scGM) for all controls and MS patients without stratifying by age:
there is a signiﬁcant decrease in global GM and subcortical GM
(scGM) volume, but not in WM or cortical GM (cGM). The percentage
differences in mean global tissue volumes for the MS group relative to
themean volumes for the control group are given in Fig. 3b. Interesting-
ly, theWM volume difference (−2.74%) is less than half that of the GM
(−6.19%), and the decrease in mean scGM volume (−13.34%) is more
than three times greater than that of the cGM (at −4.08%) in this
cohort.
Investigating differences within each age group, the plots in Fig.
4a and the data in the top third of Table 2 reveal signiﬁcant GM and
scGM volume differences between age-matched MS patients and
controls (younger: p b 0.001 for both GM and scGM; older: p =
0.001 for GM, pb 0.001 for scGM),whilst there is no signiﬁcant difference
between age-matched patients and controls for the WM and the cGM
global tissue volumes. Additionally, Fig. 4b reveals that the percentage
Fig. 2. Sample tissue segmentations after lesionmasking. Top:Manually delineated lesions, shown for two subjects (red=WM lesions, green=GM lesions) areﬁlled before segmentation
to reduce classiﬁcation errors. Bottom: Tissue volumes as deﬁned with SIENAX for global scaled volumes, and local (subcortical) tissue volumes as deﬁned with FIRST.
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ble for the younger and the older MS group (WM:−2.72% and−2.78%;
GM:−5.86% and−6.08%; cGM:−3.73% and−3.99%; scGM:−13.01%Fig. 3. Global tissue volumes: two groups. A: absolute values of the global tissue volumes for al
volume decrease of MS global tissue volumes (expressed as a percentage of the control grou
(†)survives Bonferroni correction for comparisons amongst groups.and−13.18%, respectively). Once again, the greatest atrophy is found in
the scGM global tissue volume, explored further by the evaluation of
the local (subcortical) tissue volumes below.l of the controls and the MS patients (i.e., without separation by age group). B: percentage
p mean tissue volume). Error bars are standard deviations. (***) p ≤ 0.001, uncorrected.
Fig. 4.Global tissue volumes: four groups. A: global tissue volumes for both age groups of the controls and theMSpatients. B: volume difference for theMS global tissue volumes, expressed
as a percentage change from the corresponding control group mean tissue volume. Error bars are standard deviations. (***) p ≤ 0.001, uncorrected. (†) survives Bonferroni correction.
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notable exceptions
Local (subcortical) GM tissue volumes and ANCOVA results for com-
parisons across the four groups are presented in the lower two-thirds of
Table 2, with atrophymeasures (expressed as the percentage change in
meanvolume relative to the corresponding control group) shown in Fig.
5. Both the younger and older MS patients had signiﬁcantly reduced
local GMvolume comparedwith the age-matched controls in the region
of the putamen (p b 0.001 for both), thalamus (p b=0.001 for both) and
nucleus accumbens (p b 0.001 for younger, p= 0.005 for older MS pa-
tients). In two regions – the caudate and the hippocampus - there wasTable 2
Tissue volumes and comparisons: four groups. Tissue volumes and Analysis of Covariance (AN
Values reported asmean (SD). All p-values are uncorrected formultiple comparisons. Daggers d
regions of interest (‡).
Younger control Younger MS Older control Older MS
Global level
White 732,105.8 (31,001.2) 712,226.7 (49,240.6) 732,776.1 (33,148.3) 712,422.9
Grey 831,717.9 (39,916.0) 782,947.7 (47,128.5) 784,524.5 (47,578.4) 736,858.7
cGM 656,787.4 (32,131.5) 632,263.7 (39,229.3) 621,226.4 (38,781.6) 596,443.2
scGM 174,930.6
(11,659.8)
152,175.8
(10,721.2)
163,298.2
(11,037.0)
141,774.5
(8627.0)
Regional level
Puta 13,658.9 (1312.6) 11,727.6 (1971.7) 12,850.3 (1106.1) 11,530.9 (
Caud 9888.8 (965.2) 8647.7 (842.7) 9352.6 (830.6) 8556.9 (97
Thal 21,405.1 (1292.5) 18,573.1 (1873.0) 19,924.1 (1609.5) 18,246.5 (
Hipp 10,598.2 (1131.5) 9452.6 (1438.6) 9807.3 (926.0) 9579.6 (95
Amyg 3271.4 (543.1) 2878.9 (411.8) 3156.5 (619.9) 2835.4 (52
Accu 1439.3 (199.7) 1104.1 (266.9) 1284.6 (191.2) 1088.2 (21
Pall 4740.7 (430.7) 4343.2 (584.7) 4679.7 (587.4) 4686.0 (12signiﬁcantly reduced GM volume for only the younger MS patients
(p b 0.001 for both). The volumes of the amygdala and the pallidum
were not signiﬁcantly different between the MS patients and their
age-matched control group (Table 2).
4. Discussion
This study investigated both global and local tissue volume differ-
ences in younger and older-onsetMS patients from awell-characterised
cohortwith age-matched controls. The twoMSgroupswere selected for
short clinical disease duration and matched in disease severity mea-
sured by MSSS and recent relapses. For the two-group comparison,COVA) results for the four subject groups (both MS patients and controls, young and old).
enote values that survive Bonferroni correction for comparisonwithmultiple groups (†) or
p
(yC/yMS)
p
(yC/oC)
p
(yC/oMS)
p
(yMS/oC)
p
(yMS/oMS)
p
(oC/oMS)
(38,048.7) 0.16 0.95 0.14 0.17 0.92 0.15
(44,119.2) b0.001†‡ b0.001†‡ b0.001†‡ 0.72 0.003†‡ 0.001†‡
(40,896.4) 0.011†‡ 0.001†‡ b0.001†‡ 0.60 0.007†‡ 0.028
b0.001†‡ b0.001†‡ b0.001†‡ 0.006†‡ 0.003†‡ b0.001†‡
1437.0) b0.001†‡ 0.06 b0.001†‡ 0.25 0.68 0.009
3.3) b0.001†‡ 0.04 b0.001†‡ 0.03 0.75 0.012
1629.5) b0.001†‡ 0.001†‡ b0.001†‡ 0.002†‡ 0.69 0.001†‡
3.0) b0.001†‡ 0.014 0.001†‡ 0.11 0.55 0.33
5.1) 0.026 0.45 0.012 0.15 0.77 0.09
5.7) b0.001†‡ 0.014 b0.001†‡ 0.005†‡ 0.94 0.005†‡
37.3) 0.03 0.76 0.65 0.08 0.11 0.87
Fig. 5. Local tissue volume differences for MS patients. Local (subcortical) GM volume differences for the younger and older MS patients, (A) raw values in mm3 and (B) expressed as a
percentage change from the corresponding control group mean tissue volumes. (**) p b 0.01, (***) p b 0.001, ANCOVA of normalized volumes versus age-matched control group. p-
Values uncorrected; (†)survives Bonferroni correction for comparisons amongst groups or (‡) regions of interest.
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thepercentage volume changes for cerebral GMandWMreported here-
in (−6.19% and−2.74%, respectively) are comparable to values report-
ed elsewhere for similar-age, but much longer disease duration (mean
11.3 years) MS patients (Ramasamy et al., 2009). Whilst studies have
previously identiﬁed subcortical GM atrophy in MS patients (Cifelli et
al., 2002), (Chard et al., 2004), (Bakshi et al., 2005), (Prinster et al.,
2006), (Ramasamy et al., 2009), (Audoin et al., 2010), we believe that
this is the ﬁrst study to directly compare the relative volume loss in
younger and older-onset MS of matched early clinical status.
We found that the scGM degeneration dominates over that of the
periphery. The deﬁnition of scGM included deep grey matter structures
as well as non-peripheral (e.g. not neocortex) GM, however similar vol-
ume differences were found scGM and in the deﬁned GM structures.
There is a body of evidence to suggest preferential degeneration of the
subcortical, rather than the cortical, GM tissue in MS patients. The
timecourse of this degeneration is less well explored. Bergsland et al.
(2012) found that patientswith early RRMShad signiﬁcantly lower sub-
cortical deep GM volumes, but not lower cortical volumes, compared to
Clinically Isolated Syndrome (CIS) patients. Findings of signiﬁcant re-
gional atrophy in the thalamus and putamen are similarly supported
by Ramasamy et al. (2009), whilst their observation of visible hippo-
campal atrophy only in progressive disease stages is contrary to the
signiﬁcant hippocampal atrophy in our younger cohort of early-onset
RRMS patients (disease duration of 2.29±1.6 years). Ourﬁndings how-
ever are consistentwith a number of other studies of GM (Roosendaal et
al., 2011) and hippocampal (Sicotte et al., 2008) atrophy in RRMS and
SPMS.
The novel feature and main focus of this study was to explore brain
volume differences in the clinically-matched older and younger-onset
MS groups; the rationale being that signiﬁcant differences might offer
insight into the variable age of disease onset and enable inferences on
the early-phase trajectory of CNS atrophy in these different age groups.
Furthermore, whilst this is not a longitudinal study, comparison of the
tissue volume differences in the younger and older MS patients againsttheir corresponding age-matched controls gives a measure of volume
loss separate from ‘normal’ age-related decline.
Longitudinal studies in RRMS (as well as PPMS and SPMS), have
suggested that the trajectory of CNS atrophy is initially rapid then
tails off later in the disease course (Zivadinov and Bakshi, 2004).
However, it remains unknown whether the initial rate of CNS atro-
phy differs between the younger- and older-onset MS patients dur-
ing the ﬁrst few years of disease and we sought to ascertain any
differences detectable by cross-sectional analysis within 5 years
from clinical onset.
We were unable to differentiate volume decreases in the younger
and older onset subjects at the global tissue structure level (WM, GM,
cGM and scGM). The percentage decrease in mean global tissue vol-
umes for the younger and older MS patients relative to age-matched
controls was similar. However, at a local/regional level, ﬁndings suggest
that some structures, in particular the hippocampus, have unique pat-
terns of involvement. The notable loss in the young-onset and relative
preservation in the older-onset MS patients may be indicative of early
and marked loss of neurons in hippocampal substructures, as seen in
post-mortem studies (Papadopoulos et al., 2009). Chronic GM neuroin-
ﬂammation as conﬁrmed by in-vivo PET imaging (Colasanti et al., 2015)
has been observed in the hippocampus of MS patients. Alternatively,
there may be more hippocampal atrophy in younger-onset MS patients
from the selective vulnerability of neuronal subpopulations or growth
factor dysregulations (Geurts and Barkhof, 2008), or disease heteroge-
neity resulting in an earlier disease onset. A number of studies have re-
ported worse cognitive dysfunction in early onset MS, most clearly
demonstrated in pediatric and juvenile MS (Cardoso et al., 2015;
Krysko and O'Connor, 2016). In adult onset MS, left hippocampal atro-
phy was shown to be correlated with verbal memory performance
(Sacco et al., 2015). Our observations of low hippocampal volume may
provide an imaging correlate of themoremarked cognitive impairment
previously demonstrated in younger onset MS (Hosseini et al., 2014).
Demonstration of this putative association is, however, limited by the
lack of neuropsychometric data on the current cohort.
15C.A. Bishop et al. / NeuroImage: Clinical 13 (2017) 9–15In addition to the above ﬁndings, we have demonstrated an image
analysis workﬂow for analysis of global and local tissue volumes in larg-
er MS studies. A number of fully-automated solutions are being ex-
plored (Jain et al., 2015); however in this workﬂow we opted for
manual delineation of both white and grey matter lesions. Lesions
were then ﬁlled to allow automated segmentation of tissues to produce
accurate volume measures of tissues and structures independent of le-
sion burden.We hope that thisworkﬂowwill be adopted to facilitate di-
rect comparison of future measures with those reported herein.
Our study does have limitations: (1) cross-sectional design; (2)
small sample size; (3) the protocol did not include double inversion re-
covery sequences, useful to detect hippocampal focal lesions; and (4)
neuropsychological assessments were not performed.
However, our results conﬁrm previous studies demonstrating GM
atrophy in MS and considerably extend them with the novel detection
of excess volume decreases in subcortical regions, particularly the hip-
pocampus, that play a central role in memory processing.
Further longitudinal imaging studies incorporating cognitive testing
are warranted to understand inmore depth the development of region-
al GMatrophy and any regional differences in patientswith demyelinat-
ing disease (including radiologically- and clinically isolated syndromes;
and MS), and its relationship with age and cognitive function.
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